Prediction of psychosis onset in Alzheimer disease: The role of cognitive impairment, depressive symptoms, and further evidence for psychosis subtypes

American Journal of Geriatric Psychiatry

Volumn 14, Issue 4, 2006, Pages 352-360

  Wilkosz, Patricia A ^a   Miyahara, Sachiko ^b   Lopez, Oscar L ^a   DeKosky, Steven T ^a   Sweet, Robert A ^a,c  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

Alzheimer disease; Cognition; Delusions; Hallucinations; Phenotype

Indexed keywords

ANTIDEPRESSANT AGENT; PSYCHOTROPIC AGENT;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; BEHAVIOR; CERAD BEHAVIORAL RATING SCALE; COGNITIVE DEFECT; CONTROLLED STUDY; CORRELATION ANALYSIS; DELUSION; DEPRESSION; FEMALE; FOLLOW UP; HALLUCINATION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MODEL; PARANOID PSYCHOSIS; PHENOTYPE; PSYCHOSIS; RATING SCALE; RISK ASSESSMENT; SURVIVAL; SYMPTOM;

EID: 33645777490     PISSN: 10647481     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.JGP.0000192500.25940.1b     Document Type: Article

References (41)

1. Stern Y, Mayeux R, Sano M, et al: Predictors of disease course in patients with probable Alzheimer's disease. Neurology 1987; 37:1649-1653
2. Jeste DV, Wragg RE, Salmon DP, et al: Cognitive deficits of patients with Alzheimer's disease with and without delusions. Am J Psychiatry 1992; 149:184-189
3. Rockwell E, Jackson E, Vilke G, et al: A study of delusions in a large cohort of Alzheimer's disease patients. Am J Geriatr Psychiatry 1994; 2:157-164
4. Lopez OL, Kamboh MI, Becker JT, et al: The apolipoprotein E ε4 allele is not associated with psychiatric symptoms or extrapyramidal signs in probable Alzheimer's disease. Neurology 1997; 49:794-797
5. Paulsen JS, Ready RE, Stout JC, et al: Neurobehaviors and psychotic symptoms in Alzheimer's disease. J Int Neuropsychol Soc 2000; 7:815-820
6. Drevets WC, Rubin EH: Psychotic symptoms and the longitudinal course of senile dementia of the Alzheimer type. Biol Psychiatry 1989; 25:39-48
7. Levy ML, Cummings J, Fairbanks LA, et al: Longitudinal assessment of symptoms of depression, agitation, and psychosis in 181 patients with Alzheimer's disease. Am J Psychiatry 1996; 153:1438-1443
8. Ballard CG, O'Brien JT, Coope B, et al: Psychotic symptoms in dementia and the rate of cognitive decline. J Am Geriatr Soc 1997; 45:1031-1032
9. Paulsen JS, Salmon DP, Thal L, et al: Incidence of and risk factors for hallucinations and delusions in patients with probable Alzheimer's disease. Neurology 2000; 54:1965-1971
10. McShane R, Keene J, Gedling J, et al: Do neuroleptic drugs hasten cognitive decline in dementia? Prospective study with necropsy follow up. BMJ 1997; 314:266-270
11. Lopez OL, Becker JT, Brenner RP, et al: Alzheimer's disease with delusions and hallucinations: neuropsychological and electroencephalographic correlates. Neurology 1991; 41:906-912
12. Wragg RE, Jeste DV: Overview of depression and psychosis in Alzheimer's disease. Am J Psychiatry 1989; 146:577-587
13. Sweet RA, Nimgaonkar VL, Devlin B, et al: Increased familial risk of the psychotic phenotype of Alzheimer disease. Neurology 2002; 58:907-911
14. Bacanu SA, Devlin B, Chowdari KV, et al: Linkage analysis of Alzheimer disease with psychosis. Neurology 2002; 59:118-120
15. Sweet RA, Devlin B, Pollock BG, et al: Catechol-O-methyltransferase haplotypes are associated with psychosis in Alzheimer disease. Mol Psychiatry 2005; 10:1026-1036
16. Go RC, Perry RT, Weiner H, et al: Neuregulin-1 polymorphism in late onset Alzheimer's disease families with psychoses. Am J Med Genet B Neuropsychiatr Genet 2005; 139:28-32
17. Sweet RA, Nimgaonkar VL, Kamboh MI, et al: Dopamine receptor genetic variation, psychosis, and aggression in Alzheimer's disease. Arch Neurol 1998; 55:1335-1340
18. Holmes C, Smith H, Ganderton R, et al: Psychosis and aggression in Alzheimer's disease: the effect of dopamine receptor gene variation. J Neurol Neurosurg Psychiatry 2001; 71:777-779
19. Holmes C, Arranz MJ, Powell JF, et al: 5-HT2A and 5-HT2C receptor polymorphisms and psychopathology in late onset Alzheimer's disease. Hum Mol Genet 1998; 7:1507-1509
20. Nacmias B, Tedde A, Forleo P, et al: Association between 5-HT(2A) receptor polymorphism and psychotic symptoms in Alzheimer's disease. Biol Psychiatry 2001; 50:472-475
21. Sweet RA, Panchalingam K, Pettegrew JW, et al: Psychosis in Alzheimer disease: postmortem magnetic resonance spectroscopy evidence of excess neuronal and membrane phospholipid pathology. Neurobiol Aging 2002; 23:547-553
22. Sweet RA, Hamilton RL, Healy MT, et al: Alterations of striatal dopamine receptor binding in Alzheimer's disease are associated with Lewy body pathology and with antemortem psychosis. Arch Neurol 2001; 58:466-472
23. Tariot PN, Mack JL, Patterson MB, et al: The behavior rating scale for dementia of the Consortium to Establish a Registry for Alzheimer's Disease. Am J Psychiatry 1995; 152:1349-1357
24. Rubin EH, Kinscherf BA, Morris JC: Psychopathology in younger versus older persons with very mild and mild dementia of the Alzheimer type. Am J Psychiatry 1993; 150:639-642
25. Cook SE, Miyahara S, Bacanu SA, et al: Psychotic symptoms in Alzheimer disease: evidence for subtypes. Am J Geriatr Psychiatry 2003; 11:406-413
26. Perez-Madrinan G, Cook SE, Saxton JA, et al: Alzheimer disease with psychosis: excess cognitive impairment is restricted to the misidentification subtype. Am J Geriatr Psychiatry 2004; 12:449-456
27. Lopez OL, Wisniewski SR, Becker JT, et al: Psychiatric medication and abnormal behavior as predictors of progression in probable Alzheimer disease. Arch Neurol 1999; 56:1266-1272
28. Becker JT, Boller F, Lopez OL, et al: The natural history of Alzheimer's disease: description of study cohort and accuracy of diagnosis. Arch Neurol 1994; 51:585-594
29. McKhann G, Drachman D, Folstein M, et al: Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease. Neurology 1984; 34:939-944
30. Lopez OL, Becker JT, Klunk WE, et al: Research evaluation and diagnosis of probable Alzheimer's disease over the last two decades. I. Neurology 2000; 55:1854-1862
31. Lopez OL, Becker JT, Klunk WE, et al: Research evaluation and diagnosis of possible Alzheimer's disease over the last two decades. II. Neurology 2000; 55:1863-1869
32. Lopez OL, Jagust WJ, DeKosky ST, et al: Prevalence and classification of mild cognitive impairment in the Cardiovascular Health Study Cognition Study: part 1. Arch Neurol 2003; 60:1385-1389
33. Diagnostic and Statistical Manual of Mental Health Disorders. Washington, DC, American Psychiatric Association, 1994
34. Mack JL, Patterson MB, Tariot PN: Behavior rating scale for dementia: development of test scales and presentation of data for 555 individuals with Alzheimer's disease. J Geriatr Psychiatry Neurol 1999; 12:211-223
35. Sweet RA, Nimgaonkar VL, Devlin B, et al: Psychotic symptoms in Alzheimer disease: evidence for a distinct phenotype. Mol Psychiatry 2003; 8:383-392
36. Pollock BG, Mulsant BH, Rosen J, et al: A randomized, double-blind, placebo-controlled comparison of citalopram and perphenazine for the acute treatment of psychosis and behavioral disturbances associated with dementia. Am J Psychiatry 2002; 159:460-465
37. Bassiony MM, Rosenblatt A, Baker A, et al: The relationship between delusions and depression in Alzheimer's disease. Int J Geriatr Psychiatry 2002; 17:549-556
38. Gormley N, Rizwan MR: Prevalence and clinical correlates of psychotic symptoms in Alzheimer's disease. Int J Geriatr Psychiatry 1998; 13:410-414
39. Wynn ZJ, Cummings JL: Cholinesterase inhibitor therapies and neuropsychiatric manifestations of Alzheimer's disease. Dement Geriatr Cogn Disord 2004; 17:100-108
40. Tariot PN, Farlow MR, Grossberg GT, et al: Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA 2004; 291:317-324
41. Sweet RA, Pollock BG, Sukonick DL, et al: The 5-HTTPR polymorphism confers liability to a combined phenotype of psychotic and aggressive behavior in Alzheimer's disease. Int Psychogeriatr 2001; 13:401-409